Cotargeting BCL-2 and MCL-1 in high-risk B-ALL

Donia M. Moujalled,1,2,* Diane T. Hanna,3–5,* Soroor Hediyeh-zadeh,3,4 Giovanna Pomilio,1,2 Lauren Brown,6 Veronique Litalien,1 Ray Bartolo,5 Shaun Fleming,2 Maïa Chanrion,7 Sébastien Banquet,6 Ana-Leticia Maragno,1 Laurence Kraus-Berthier,8 Marie Schoumacher,9 Charles G. Millighan,9 Angela Georgiou,3 Christine A. White,3,4 Guillaume Lessene,3,4 David C. S. Huang,3,4 Andrew W. Roberts,3,4,10 Olivier Geneste,7 Lorna Rasmussen,11 Melissa J. Davis,3,4 Paul G. Ekert,6 Andrew Wei,1,2,† Ashley P. Ng,3,4,10,† and Seong L. Khaw4–6,†

1Australian Centre for Blood Diseases, Monash University, Melbourne, Australia; 2Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia; 3The Walter and Eliza Hall Institute, Parkville, Melbourne, Australia; 4Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Australia; 5The Royal Children’s Hospital, Parkville, Melbourne, Australia; 6Murdoch Children’s Research Institute, Parkville, Melbourne, Australia; 7Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France; 8Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France; 9St Jude Children’s Research Hospital, Memphis, TN; 10Clinical Haematology, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital, Parkville, Melbourne, Australia; and 11Cerberus Sciences, Melbourne, Australia

Key Points

• BCL-2 and MCL-1 inhibitors synergize in vitro and demonstrate potent activity in vivo against high-risk B-ALL patient-derived xenografts.
• The combination can induce tumor lysis syndrome in PDX models, indicating that appropriate precautions will be needed in clinical trials.

Introduction

Although cure rates in pediatric precursor B acute lymphoblastic leukemia (B-ALL) approach 90%, only 30% to 40% of adult patients achieve long-term remission.1 Targeting antiapoptotic BCL-2 family proteins (BCL-2,2–4 BCL-XL,5 MCL-16) is an emerging therapeutic strategy in a range of leukemias. The selective BCL-2 inhibitor venetoclax has shown impressive efficacy in chronic lymphocytic leukemia3 and acute myeloid leukemia (AML),7 and in combination with BCL-XL inhibition (via navitoclax) in pediatric and adult relapsed or refractory B-ALL.8 S64315, a selective MCL-1 inhibitor and derivative of S63845,9 has entered clinical trials for AML, multiple myeloma, and lymphoma. BCL-2 and MCL-1 have been identified as important prosurvival proteins across multiple acute lymphoblastic leukemia (ALL) subtypes, including MLL-rearranged (KMT2A) ALL9–11 and BCR-ABL1 (Ph+) ALL,12 where combination ABL1 and BCL-2 inhibition appears synergistic in patient-derived xenograft (PDX) models.13,14 We have previously shown that S63845 is better tolerated by normal human CD3415,16 progenitor cells than standard cytotoxic drug combinations,

Submitted 30 December 2019; accepted 19 April 2020; published online 22 June 2020. DOI 10.1182/bloodadvances.2019001416.
*D.M.M. and D.T.H. contributed equally to this study.
†A.W., A.P.N., and S.L.K. contributed equally to this study as senior authors.

Send data sharing requests to Donia M. Moujalled (donia.moujalled@monash.edu) or Diane T. Hanna (hanna.d@wehi.edu.au).
The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology
Figure 1.
and combined targeting of BCL-2 and MCL-1 was synergistic in preclinical AML models. Here, we have explored the efficacy of combined BCL-2 and MCL-1 inhibitors in preclinical models of BCR-ABL1 positive (Ph⁺), Ph-like (BCR-ABL1 negative ALL) with kinase activating genetic alterations and blast gene expression profile similar to BCR-ABL1 ALL,17 and other subtypes of human B-ALL (Ph⁺).

**Methods**

**In vitro cytotoxicity and drug synergy assays**

Primary B-ALL patient BM samples (blasts >60%) and cell lines were incubated in drug concentrations between 1 nM and 10 μM for 48 hours or 96 hours, respectively. Cell viability was determined by SYTOX Blue Dead Cell Stain (S34857; Life Technologies) using an LSR-Fortessa (BD), and fluorescence-activated cell sorting data were analyzed using FlowJo as previously described.14,18

**Event-free survival assays**

NSG mice were injected IV with 1 × 10⁶ ALL cells. In vivo treatment commenced initially upon 5% hCD45⁺ cells in peripheral blood and 1% after animal ethics committee review following acute tumor lysis syndrome (ATLS) was observed with combination treatment. A minimum of 6 mice received each treatment: vehicle, venetoclax (oral gavage; 25 mg, 50 mg, or 100 mg/kg per day, 5 days per week for 3 weeks), S63845 (3 mg/kg, 6 mg/kg, 12.5 mg/kg, or 25 mg/kg IV, twice weekly for 3 weeks), and ruxolitinib (90 mg/kg per day, 5 days per week for 3 weeks) alone (and in combination). Human leukemia burden in blood was measured weekly by flow cytometry, and mice were examined daily and euthanized if found to be unwell (e.g., rough coat, failure to thrive, decreased activity, panting, circling, grinding teeth). Peripheral blood blast levels were compared with gauge efficacy and ≥25% hCD45⁺CD19⁻ defined as an event after animal ethics committee review. Histology was performed using institutional and independent external (Cerberus) review.

**Results and discussion**

**Combined targeting of BCL-2 and MCL-1 synergistically induces apoptosis in vitro in high-risk B-ALL**

We investigated whether selective BCL-2 (venetoclax) or MCL-1 (S63845) inhibitors enhanced the efficacy of tyrosine kinase inhibitors (TKIs), standard of care chemotherapeutic agents, or selective BH3-mimetics in 7 B-ALL cell lines. Venetoclax, but not S63845, strongly potentiated the activity of all TKIs tested in Ph⁺ ALL, including TKIs not generally regarded as ABL1 inhibitors (Figure 1A). In contrast, TKI potentiation was not seen with either BH3-mimetic in CRLF2-rearranged Ph-like ALL cell lines, despite increased BIM expression following TKI exposure in both Ph⁺ and Ph-like ALL cell lines (supplemental Figure 1A). Furthermore, venetoclax and S63845 enhanced the efficacy of dexamethasome across Ph⁺, Ph⁻ (including KMT2A-ALL) and Ph-like cell lines, and primary patient samples (Figure 1A; supplemental Figure 1B). The addition of venetoclax or S63845 markedly potentiated the modest killing observed with targeting BCL-2, MCL-1, or BCL-X₁ alone, across almost all cell lines (Figure 1A), and equimolar combinations of BCL-2 and MCL-1 inhibitors demonstrated potent killing (50% lethal concentration [LC₅₀] < 100 nM) in 6 of 7 B-ALL cell lines (Figure 1A). This included both Ph⁺ and Ph-like cell lines, where every pairwise BH3-mimetic combination tested demonstrated more consistent and potent synergy than combining each BH3-mimetic with either TKI or steroids (Figure 1A). This was recapitulated in vitro in a panel of Ph⁺ and Ph-like ALL PDXs (supplemental Figure 1C; supplemental Table 2). BH3-mimetic combinations demonstrated especially potent synergy (Bliss Sums >1000) in Ph-like ALL (supplemental Figure 1C-D). Similarly, in primary B-ALL patient samples, a minority was sensitive to selective targeting of BCL-2, MCL-1, or BCL-X₁ alone; however, simultaneous targeting of MCL-1 and either BCL-2 (venetoclax or S63845) or BCL-X₁ demonstrated potent killing in 15 of 24 and 9 of 20 of samples, respectively. Notably, >50% of Ph⁺ and Ph⁻ primary ALL samples were sensitive to combined BCL-2 and MCL-1 inhibition (Figure 1B; supplemental Table 1).

**Transcriptional profiling of B-ALL samples and computational modeling identifies potential mediators of resistance to combined BCL-2 and MCL-1 inhibition**

To understand whether the LC₅₀ of primary ALL samples to combined BCL-2 and MCL-1 inhibition was predicted by the expression of BCL-2 family genes, samples were classified as sensitive (LC₅₀ < 10 nM) or resistant (LC₅₀ > 100 nM), and a Support Vector Classifier approach and logistic regression with group lasso penalty applied to log₂ CPM RNA-seq values (Figure 1C; supplemental Figure 2). These 2 independent approaches identified that pretreatment expression levels of antiapoptotic BCL-2, MCL1, BCL2L1, and BCL2L12 correlated with resistance, while expression of proapoptotic BH3-only genes HRK, BMF, BAD, BIK, and PMAIP1 correlated with sensitivity.
Figure 2. Interrogating prosurvival protein dependency in vivo in Ph\(^+\), Ph-like, and Ph\(^-\) B-ALL PDX using BH3-mimetic drugs alone and in combination. (A) Irradiated NSG mice were transplanted with 1 \(\times\) 10\(^6\) primary B-ALL cells (Ph\(^-\) 01-160-2015 or Ph\(^+\) 01-228-2012). Engraftment was confirmed at 6 weeks by detection of hCD45 in peripheral blood. Cohorts of 4 mice per group were then treated with (i) vehicle, (ii) S55746 (BCL-2 inhibitor), (iii) S63845 (MCL-1 inhibitor) or (iv) S55746 combined with S63845, and (v) dasatinib or (vi) dasatinib + S55746 (for 01-228-2012). Mice were euthanized on day 8, and immunohistological analysis for hCD45\(^+\) was performed on sternal bone marrow and spleen for infiltration by B-ALL cells captured at 100\(\times\) magnification using the Aperio ScanScope. Representative cases from each cohort are shown. Flow cytometric analysis of flushed femurs showing the percentage of human CD45\(^+\) cells from B-ALL 01-160-2015 or 01-228-2012 after indicated treatments (mean ± standard deviation and individual mouse values shown). B-ALL 01-160-2015 vehicle (n = 4), S63845 (n = 4), S55746 (n = 5), S55746+S63845 (n = 5). B-ALL 01-228-2012 vehicle (n = 4), S63845 (n = 3), S55746 (n = 3), S55746+S63845 (n = 4), dasatinib (n = 3), dasatinib + S63845 (n = 4). (B-C) NSG mice were transplanted with 1 \(\times\) 10\(^6\) Ph-like ALL cells (P2RY8-CRLF2-IR682RG). Leukemia engraftment and progression were assessed in groups of 6 female mice per treatment arm as shown with dosage regimen described in the “Methods.” (B) Treatment began when the mice engrafted 1% to 5% and human CD45\(^+\) cells and CD19\(^+\) proportion in peripheral blood (% hCD45\(^+\)CD19\(^+\)) were monitored weekly. \(\ast\) \(P\leq 0.0024\) for Venetoclax + S63845 compared to vehicle by Mantel-Cox test. (C) Representative recipient sternal sections stained for hCD19 and hCD45 after treatment with vehicle (top) or Venetoclax + S63845 (middle and bottom, 2 independent recipients). Images taken at 20\(\times\) magnification using the Panoramic Scan II by 3D Histech. (D) When venetoclax and S63845 were combined, fatal murine ATLS was observed with multiorgan involvement consisting of widely disseminated microemboli composed of nuclear and cytoplasmic debris derived from lysed leukemia cells, seen as deeply basophilic homogenous material as indicated by the arrows in spleen, lung, and kidney glomeruli.\(\ast\)\(\ast\) Images captured using the Olympus Model BX41 and Olympus U-CMAD 3 camera at 200\(\times\) magnification (spleen and lung) and 400\(\times\) magnification (kidney). H&E, hematoxylin and eosin.
Combined BCL-2 and MCL-1 inhibition in vivo has potent antileukemia activity in high-risk B-ALL PDXs

We next tested escalating in vivo doses of both venetoclax and S63845 in combination in nonleukemia-bearing NSG mice. Venetoclax up to 100 mg/kg with S63845 up to 12.5 mg/kg was well tolerated with no impact on blood counts or weight (supplemental Figure 3). However, in the cohorts receiving S63845 25 mg/kg with venetoclax at 3 dose levels (25/50/100 mg/kg per day), 7 of 12 mice in the lower-dose cohorts died with postmortem findings demonstrating bone marrow hypopcellularity that was discordant with normal blood counts, and multorgan edema, but precise causality could not be ascribed. All 6 mice receiving the highest doses (venetoclax 100 mg/kg and S63845 25 mg/kg) remained well. Although the latter suggests the deaths may not have been dose related, S63845 was limited to 12.5 mg/kg in combination therapy by the institutional animal ethics committee for the subsequent efficacy experiments.

To validate the observed efficacy of BCL-2 and MCL-1 inhibition in vivo, B-ALL PDX models were treated with a BCL-2 inhibitor (venetoclax or S55746), alone or combined with S63845, and/or kinase inhibitor if a targetable lesion was present. First, efficacy was evaluated in Ph+- and Ph- ALL PDXs after 5 days of treatment. Combined BCL-2 and MCL-1 inhibition demonstrated potent activity in the 2 Ph+-ALL PDXs and was as potent as dasatinib alone or in combination with BCL-2 inhibition (Figure 2A; supplemental Figure 4A) while being well tolerated (supplemental Figure 4B-C).

We then treated cohorts of a Ph-like ALL PDX with P2RY8-CRLF2 and JAK2 mutation with different combinations of venetoclax, S63845, and ruxolitinib. Combined venetoclax and S63845 showed greater efficacy than each drug alone and other combinations (Figure 2B-C). Importantly, in 2 independent experiments, 4 of 21 mice had confirmed histological features of ATLS,19,20 having become unwell or dying within hours of receiving S63845 in addition to venetoclax (Figure 2D) with a high circulating tumor burden at time of treatment (supplemental Figure 5A).

To minimize the risk of ATLS in subsequent experiments, treatment was commenced at a lower tumor burden (median 1% engraftment) using lead-in and lower final doses of venetoclax. Using this regimen, venetoclax and S63845 combined was superior to either alone with statistically significant lower leukemia burden in the blood at assayed time points (supplemental Figure 5B) and longer event-free survival with leukemia burden <25% (supplemental Figure 5C).

In summary, we have demonstrated that dual BCL-2 and MCL-1 inhibition induces synergistic killing in vitro and rapid cytiderepression in vivo in several high-risk B-ALL models, including BCR-ABL1 and CRLF2-rearranged subtypes. Concurrent BCL-2 and MCL-1 inhibition was comparable or superior to dasatinib combined with each BH3-mimetic in Ph+ ALL and was highly active in subtypes of B-ALL for which no targetable kinase lesion was identified, with ATLS observed in some mice. Notably, concurrent BCL-2 and MCL-1 inhibition was superior to each BH3-mimetic combined with ruxolitinib in Ph-like B-ALL, where the latter agent demonstrated limited efficacy. Simultaneous BCL-2 and MCL-1 inhibition appears to have a novel breadth of potency across high-risk B-ALL subtypes, including Ph-like ALL, with resistance predicted by the expression level of BCL2 family antiapoptotic genes BCL-2, MCL-1, and BCL2L1. We conclude that this approach warrants clinical trials, which should include mandatory tumor lysis precautions and monitoring for hematologic and nonhematologic toxicity with combination therapy.

Acknowledgments

This work was supported by the National Health and Medical Research Council program grant GNT1119577 (A.W.R.), project grants GNT1060179 and GNT1122783 (A.P.N.), Cancer Council Victoria, Victorian Cancer Agency, Leukaemia Foundation of Australia, Leukemia and Lymphoma Society (Specialized Center of Research) grant 20454683, Australian Cancer Research Foundation, Monash Partners, the Alfred Foundation, and the Medical Research Future Fund, Children’s Cancer Foundation, The Department of Health and Human Services through the Victorian Cancer Agency (S.L.K.), as well as by philanthropic support from the Walter and Eliza Hall Institute, and operational infrastructure grants through the Australian Government Independent Research Institute Infrastructure Support Scheme and the Victorian Government Operational Infrastructure Support. This work has received funding support from Servier.

Authorship

Contribution: S.L.K., A.P.N., A.W., P.G.E., A.W.R., D.C.S.H., D.M.M., and D.T.H. conceptualized the study; S.L.K., A.P.N., A.W., P.G.E., D.M.M., D.T.H., S.H.-z., M.J.D., O.G., and L.R. provided the methodology; S.H.-z. and M.J.D. provided the software; S.L.K., A.P.N., A.W., P.G.E., A.W.R., D.C.S.H., D.M.M., and D.T.H. provided the validation; S.L.K., A.P.N., A.W., P.G.E., A.W.R., D.C.S.H., D.M.M., D.T.H., S.H.-z., and M.J.D. performed the formal analysis; D.M.M., D.T.H., A.G., L.B., C.A.W., S.H.-z., M.J.D., G.P., L.K.-B., R.B., and P.G.E. performed the investigation; C.G.M., M.C., S.B., V.L., S.F., A.-L.M., L.K.-B., M.S., G.L., O.G., L.R., and C.A.W. were responsible for the resources; D.M.M., D.T.H., S.L.K., A.P.N., A.W., A.W.R., C.G.M., S.H., and M.J.D. wrote the manuscript; D.M.M., D.T.H., S.H., S.L.K., and A.P.N. were responsible for the visualization; S.L.K., A.P.N., A.W., P.G.E., A.W.R., C.A.W., and D.C.S.H. supervised the study; S.L.K., A.P.N., and A.W. were responsible for project administration; and S.L.K., A.W., P.G.E., A.W.R., and D.C.S.H. acquired the funding.

Conflict-of-interest disclosure: A.G., A.P.N., A.W.R., C.A.W., D.C.S.H., G.L., S.H.-z., and M.J.D. are employees of the Walter and Eliza Hall Institute, which receives milestone and royalty payments related to venetoclax. A.W., D.M.M., and P.G.E. receive royalty payments related to venetoclax. A.W., A.W.R., D.M.M., and G.L. have received research funding from Servier. A.W.R., A.W., D.C.S.H., G.L., S.H.-z., and M.J.D. are recipients of a share in royalty payments paid to the Walter and Eliza Hall Institute of Medical Research. A.W.R. has received research funding from AbbVie, Genentech, Janssen, and BeiGene. C.G.M. has received research funding from AbbVie, Pfizer, Loxo Oncology, Amgen, and Illumina. G.L. has received research funding from Genentech and Anaxis Pharma. S.L.K. has received research funding from AbbVie, Novartis, Jazz Pharmaceuticals, and Bristol-Myers Squibb. A.-L.M., M.S., O.G., and S.B. are employees of Servier. The remaining authors declare no competing financial interests.

ORCID profiles: S.H.-z., 0000-0001-7513-6779; L.B., 0000-0002-4322-8203; C.G.M., 0000-0002-1871-1850; G.L., 0000-0002-1193-8147; D.C.S.H., 0000-0002-3101-4873; A.W.R., 0000-0002-7341-5720; M.J.D., 0000-0003-4864-7033; P.G.E., 0000-0002-2976-8617; A.P.N., 0000-0001-9690-0879.

Correspondence: Donia M. Moujalled, Australian Centre for Blood Diseases, Australian Centre for Blood Diseases, Monash University, Level 1 Walkway via The Alfred Centre, 99 Commercial Rd, Melbourne, VIC 3004, Australia; e-mail: donia.moujalled@monash.edu.
1. Jabbour E, O’Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. *Cancer*. 2015;121(15):2517-2528.

2. Souers AJ, Levenston JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat Med*. 2013;19(2):202-208.

3. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. *N Engl J Med*. 2016;374(4):311-322.

4. Casara P, Davidson J, Claperon A, et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. *Oncotarget*. 2018;9(28):20075-20088.

5. Lessene G, Czabotar PE, Sleebs BE, et al. Structure-guided design of a selective BCL-X(L) inhibitor. *Nat Chem Biol*. 2013;9(6):390-397.

6. Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. *Nature*. 2016;538(7626):477-482.

7. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. *Blood*. 2019;133(1):7-17.

8. Lacayo NJ, Pullarkat VA, Stock W, et al. Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma [abstract]. *Blood*. 2019;134(suppl_1). Abstract 285.

9. Brown LM, Hanna DT, Khaw SL, Ekert PG. Dysregulation of BCL-2 family proteins by leukemia fusion genes. *J Biol Chem*. 2017;292(35):14325-14333.

10. Benito JM, Godfrey L, Kojima K, et al. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. *Cell Rep*. 2015;13(12):2715-2727.

11. Khaw SL, Suryani S, Evans K, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. *Blood*. 2016;128(10):1382-1395.

12. Koss B, Morrison J, Perciavalle RM, et al. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. *Blood*. 2013;122(9):1587-1598.

13. Leonard JT, Rowley JS, Eide CA, et al. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. *Sci Transl Med*. 2016;8(354):354ra114.

14. Roberts KG, Yang YL, Payne-Turner D, et al. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. *Blood Adv*. 2017;1(20):1657-1671.

15. Jain N, Roberts KG, Jabbour E, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. *Blood*. 2017;129(5):572-581.

16. Moujalled DM, Porrello G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. *Leukemia*. 2018;32(4):905-917.

17. Mullighan CG, Su X, Zhang J, et al; Children’s Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *N Engl J Med*. 2009;360(5):470-480.

18. Powell JA, Thomas D, Barry EF, et al. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. *Blood*. 2009;114(23):4859-4870.

19. Radaelli E, Marchesi F, Patton V, Scanziani E. Diagnostic exercise: sudden death in a mouse with experimentally induced acute myeloid leukemia. *Vet Pathol*. 2009;46(6):1301-1305.

20. Treuting PM, Albertson TM, Preston BD. Case series: acute tumor lysis syndrome in mutator mice with disseminated lymphoblastic lymphoma. *Toxicol Pathol*. 2010;38(3):476-485.